Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 5/20 | 0.34 |
| ▸ | NOS2 | P35228 | 5/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | RET | P07949 | 2/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12540026 | 1.00 | ESR2 (0.35) | ESR2NOS3NOS2USP7MEN1 | |
| SCHEMBL3388421 | 0.83 | NOS3 (0.37) | NOS3NOS2USP7NOS1ADK | |
| SCHEMBL17967836 | 0.79 | ROCK1 (0.41) | MEN1KMT2A | |
| SCHEMBL4367345 | 0.72 | ROCK1 (0.39) | — | |
| SCHEMBL4367350 | 0.72 | ROCK1 (0.39) | — | |
| SCHEMBL23901911 | 0.72 | USP7 (0.35) | NOS3NOS2USP7NOS1 | |
| SCHEMBL28907422 | 0.72 | NOS3 (0.37) | NOS3NOS2USP7MEN1GAA | |
| SCHEMBL22493647 | 0.72 | USP7 (0.35) | NOS3NOS2USP7NOS1RET | |
| SCHEMBL26686534 | 0.72 | USP7 (0.35) | NOS3NOS2USP7GAANOS1 | |
| SCHEMBL26471836 | 0.72 | USP7 (0.35) | NOS3NOS2USP7NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937349-B1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160368933-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-9359355-B2 | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 | AMGEN INC. (US) | 2016-06-07 | — | — | US | disclosed |
| EP-2937349-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2688887-B1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20140163052-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8623885-B2 | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 | AMGEN INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120244110-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163052-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | CDK6, CDKL4, CDK16 | ESR2 2184/4885NOS3 3520/4885NOS2 3666/4885 |
| US-20120244110-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | CDK6, CDKL4, CDK16 | ESR2 2184/4885NOS3 3520/4885NOS2 3666/4885 |
| US-20160368933-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | CDK6, CDKL4, CDK16 | ESR2 2184/4885NOS3 3520/4885NOS2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.